Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile MDM2 amp TP53 wild-type
Therapy Alrizomadlin
Indication/Tumor Type liposarcoma
Response Type predicted - sensitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
MDM2 amp TP53 wild-type liposarcoma predicted - sensitive Alrizomadlin Case Reports/Case Series Actionable In a Phase I trial, Alrizomadlin (APG-115) treatment demonstrated safety in patients with advanced solid tumors, with an overall response rate of 10% (2/20, partial responses) and stable disease in 50% (10/20) of evaluable patients and a median progression-free survival (PFS) of 6.1 months, with an overall response rate of 25% (2/8) and disease control rate of 100% (8/8) in liposarcoma patients with wild-type TP53 and MDM2 amplification (PMID: 39002360). 39002360
PubMed Id Reference Title Details
(39002360) A first-in-human phase I study of a novel MDM2/p53 inhibitor alrizomadlin in advanced solid tumors. Full reference...